Haleon plc (NYSE:HLN) Shares Bought by Cerity Partners LLC

Cerity Partners LLC lifted its stake in shares of Haleon plc (NYSE:HLN) by 23.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 576,533 shares of the company’s stock after purchasing an additional 109,311 shares during the period. Cerity Partners LLC’s holdings in Haleon were worth $6,100,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Manning & Napier Advisors LLC acquired a new position in Haleon during the second quarter worth $2,833,000. Chartwell Investment Partners LLC boosted its position in shares of Haleon by 107.8% during the 3rd quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock valued at $5,030,000 after acquiring an additional 246,594 shares during the last quarter. Cetera Advisors LLC grew its holdings in shares of Haleon by 524.3% in the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock valued at $696,000 after purchasing an additional 68,857 shares during the period. Cetera Investment Advisers increased its position in Haleon by 106.3% during the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its stake in Haleon by 55.6% during the third quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company’s stock worth $5,087,000 after purchasing an additional 171,877 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HLN. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating for the company. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Morgan Stanley increased their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Haleon has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Stock Up 1.4 %

Haleon stock opened at $9.73 on Thursday. The company has a market capitalization of $44.02 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 2.89 and a beta of 0.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The firm has a 50 day moving average price of $9.97 and a 200 day moving average price of $9.41.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.